Vyome Holdings, Inc. develops clinical-stage specialty pharmaceutical therapies for immune-inflammatory and rare conditions. Company news centers on VT-1953, a topical gel program for malodor and other symptoms of malignant fungating wounds in cancer patients, and VT-1908, a repurposed immune modulator being studied for uveitis.
Recurring updates include clinical and preclinical data presentations, regulatory submissions and development planning, capital-structure actions, material agreements, shareholder voting matters, and operating or financial results tied to Vyome’s pharmaceutical and biotechnology activities.
Vyome Holdings (NASDAQ:HIND) has announced positive interim results from its Phase 2 proof-of-concept study of VT-1953 topical gel for treating malignant fungating wounds (MFW). The study demonstrated statistically significant improvements in the primary endpoint of reducing wound-associated malodor (P<0.001), as well as secondary endpoints including lesion pain reduction and quality of life improvement.
MFW affects 5-14% of advanced cancer patients, with an estimated 650,000 patients in the US and 10 million globally. The company estimates a $1 billion market opportunity in the United States alone. VT-1953 has shown good tolerability in over 500 patients, with no clinically significant adverse effects reported. Vyome plans to interact with the FDA in early 2026, with full results expected in October 2026.
Vyome Holdings (NASDAQ:HIND), a clinical-stage healthcare holding company, has signed a non-binding Memorandum of Understanding (MoU) with Embryyo Technologies, an Indian medical device innovation studio. The partnership aims to explore opportunities in the AI-enabled medical device market.
The collaboration combines Vyome's healthcare industry experience and resources with Embryyo's medical technology capabilities to develop smart medical devices for disease management and treatment. Embryyo's portfolio includes developments in interventional oncology, surgery, wearables, and drug delivery. As part of the initiative, both companies will host a global AI-enabled medical device innovation forum focusing on the US-India corridor.
Vyome Holdings (Nasdaq: HIND), a clinical-stage healthcare holding company, has announced a strategic review of its 70% controlling stake in Livechain Inc. (OTCID: LICH). The Board of Directors will spend the next month evaluating various options for Livechain.
The strategic alternatives under consideration include launching a new business, forming a crypto treasury, pursuing a merger, or selling the asset. Vyome initially acquired its controlling interest in LICH in 2021 with plans to establish a viable publicly traded business on the OTC market. With Vyome now trading on Nasdaq, the company is exploring new opportunities for its Livechain investment.
Vyome Holdings (Nasdaq: HIND), a clinical-stage healthcare company, marks its first day of trading on Nasdaq by ringing the opening bell, coinciding with India's 79th Independence Day. The company focuses on developing treatments for immuno-inflammatory and rare diseases in the US and global markets.
The company emphasizes its debt-free status and shareholder-aligned board structure. Vyome's pipeline targets the $100 billion immuno-inflammatory market, leveraging talent from both the US and India. The leadership team includes Chairman Krishna Gupta, Founder Shiladitya Sengupta (Associate Professor at Harvard Medical School), and Co-founder and CEO Venkat Nelabhotla.
Vyome Therapeutics has completed its previously announced merger with ReShape Lifesciences (Nasdaq: RSLS). The combined entity, to be known as Vyome Holdings, will begin trading on Nasdaq under the new ticker symbol "HIND" on August 15, 2025. Vyome is a clinical-stage healthcare company focused on developing treatments for immuno-inflammatory and rare diseases in US and global markets.